AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05331014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LivaloV
Description: For 8 weeks(PO, QD)
Study NCT05331014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VA
Description: For 8 weeks(PO, QD)
Study NCT04238390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane-Tazobactam
Description: Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
Study NCT04238390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
Study NCT04842201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: subcutaneous injection
Study NCT04842201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study NCT06307912 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video placebo communication
Description: The placebo communication video comprises of an educational VR video containing placebo enhancing verbal language.
Study NCT06307912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video nocebo communication
Description: The nocebo communication video comprises of an educational VR video containing nocebo enhancing verbal language.
Study NCT05517642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Description: Subjects will be randomized to receive a second booster dose of IH Convidecia vaccine (treatment arm)
Study NCT05517642 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine BNT162b2 (Pfizer)
Description: Subjects will be randomized to receive a second booster dose of BNT162b2.
Study NCT04755595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox Cosmetic Injectable Product
Description: Acetylcholine release inhibitor and a neuromuscular blocking agent
Study NCT04755595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma XC
Description: Gel implants consisting of cross-linked hyaluronic acid
Study NCT04755595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm Volbella XC
Description: Gel implants consisting of cross-linked hyaluronic acid
Study NCT06422793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No NG tube gastric decompression
Description: Participants in this group will not undergo gastric decompression following orthognathic surgery at our institution.
Study NCT05353829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: When accepted inclusion the patient will be included in SRQ, and thereafter randomised for Methotrexate per oral or subcutaneous administration
Study NCT05136937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: Administered by intratumoral injection for 3 dose cohorts: 1×10\^7 TCID50/mL, 1×10\^8 TCID50/mL and 7×10\^8 TCID50/mL
Study NCT05520983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Teens Achieving Mastery over Stress (TEAMS) Treatment
Description: Teens Achieving Mastery over Stress (TEAMS) has been adapted for use with youth with I/DD. The intervention consists of virtual, manualized treatment groups for 10 weekly, 75-minute sessions plus 6 monthly, 60-minute sessions. Caregivers of participants will meet twice: weeks one and 16.
Study NCT05520983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Teens Achieving Mastery over Stress (TEAMS) Prevention
Description: Teens Achieving Mastery over Stress (TEAMS) has been adapted for youth with I/DD. TEAMS Prevention is a 10-session group depression prevention program teaching teens how to deal with stress and negative moods, and ways to manage low mood based on cognitive behavioral therapy (CBT) principles and strategies. Efficacy has been demonstrated by several trials over time.
Study NCT05520983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT)
Description: Competent Adulthood Transition with Cognitive-behavioral \& Interpersonal Training (CATCH-IT) has been adapted for youth with I/DD. CATCH-IT is an internet-based depression prevention program that targets decreasing modifiable risk factors while enhancing protective factors in at-risk adolescents, and that includes a parent program. It has been shown to be safe, feasible, and efficacious. All adolescents will receive 8 engagement texts during their participation in the study - at 1-week, 1-month, 6-weeks, and 2-, 3-, 5-, and 5.5-months - to encourage participation in the online modules.
Study NCT05520983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening Families
Description: The Strengthening Families caregiving curriculum is an evidence-based, self-directed, virtual skills training for caregivers. Information and instructions on accessing the Strengthening Families parenting skills training curriculum will be included on the virtual resource website https://strengtheningfamilieslessons.org/.
Study NCT05520983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual psycho-educational discussion groups for caregivers and participants
Description: The BEST project will host a total of 10 virtual psycho-educational workshops per year (5 for participants and 5 for caregivers) for the duration of the intervention period of the study. Workshops will be delivered remotely via Zoom and facilitated by graduate students in health/behavioral health. Simultaneous language interpreter services will be provided. Principles of universal design in learning will be applied to the content and delivery of workshops. Workshops are an optional resource available to all participants and families in the intervention condition. Topics for the virtual discussion groups will be determined based on pilot data and input from participants and caregivers.
Study NCT05520983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maternal Child Health Bureau (MCHB) Care Coordination
Description: MCHB Care Coordination, funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, is the oldest and most universal care coordination model for children with I/DD. MCHB Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
Study NCT05520983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Child Health Bureau (MCHB) Care Coordination
Description: MCHB Care Coordination, funded through the Social Security Act of 1935 Title V Maternal and Child Health Services Block Grant Program, is the oldest and most universal care coordination model for children with I/DD. MCHB Care Coordination involves: comprehensive needs assessments, person-centered planning, and linkage to health care and social resources. MCHB care coordination has established efficacy, feasibility, and acceptability in improving child and family functioning, youth health, and health care access.
Study NCT05166694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-Drug Interaction Profile
Description: A profile based on genetic testing that shows information about how the participant's medications they are taking interact with each other.
Study NCT05166694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-Gene Interaction Profile
Description: A profile based on genetic testing that shows information about how the participant's genes interact with/respond to certain medications they are taking.
Study NCT05166694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard treatment and prescribing for the participant's specific type of cancer.
Study NCT05079503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN-001
Description: GEN-001, Lactobacillus lactis is a live, purified facultative anaerobic gram-positive probiotic lactic acid bacterial strain. GEN-001 is orally administered once daily during total TNT periods.
Study NCT05979610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Description: Reiki therapy is a form of energy healing that originated in Japan. It involves the transfer of energy from the Reiki practitioner to the recipient through the hands, with the goal of promoting physical, emotional, and spiritual well-being. Below is a general outline of the process of Reiki therapy, which may vary slightly depending on the needs of the recipient:~* The patient will be in a quiet clinic room lying in the supine position with calming music playing and aromatherapy if the patient chooses.~* The Reiki therapist will place their hands on or near the recipient's body. The Reiki therapist may use a series of hand positions that correspond to different energy centers in the body.~* During the treatment, the practitioner channels energy into the recipient's body through their hands. The patient may feel a sense of warmth, tingling, or relaxation.~* The Reiki therapist may use different techniques, such as hand movements or visualization.
Study NCT06010966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: intermittent theta-burst stimulation (iTBS)
Study NCT06010966 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: intermittent theta-burst stimulation (iTBS)
Study NCT05144607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Pressure curve (Pmus)
Description: The intervention will be the display of an additional curve - the estimated inspiratory muscle pressure waveform generated using an artificial intelligence algorithm.
Study NCT05006885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)
Study NCT05006885 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study NCT05313061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX continuation
Study NCT05313061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX continuation
Study NCT05873244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabadinostat (CXD101) and Geptanolimab
Description: * Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks
Study NCT05873244 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib and Sorafenib
Description: Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily
Study NCT04813471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endothelial Protocol
Description: Endothelial Protocol
Study NCT04797143 — intervention group
Intervention type: DEVICE
Intervention: multidisciplinary consultation program
Description: The multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).
Study NCT05053295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous activated T lymphocyte
Description: Drug: Immuncell-LC IV~Drug: Nivolumab (Opdivo®) IV
Study NCT06296862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension Diet
Description: The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets. The chosen 4 week intervention duration phase is consistent with previous research showing positive effects of consuming a sodium-reduced dietary intervention on volume status and is longer than in other studies showing positive effects of DASH diet consumption on cardiac outcomes among HF patients. Potential carryover effects are minimized by a washout period of 4 weeks. The meal plan has been previously developed based on NHLBI guidelines for the DASH diet.
Study NCT05229146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: Episodic future thinking (EFT) includes a focus on generating detailed and vivid descriptions of future events. For the current intervention, EFT will be modified to have mothers describe specific events with their children.
Study NCT05150379 — intervention group
Intervention type: OTHER
Intervention: Different exercises with their shoulders
Description: * Y Balance Test~* Shoulder rotator muscle isometric maximum strength~* One handed medicine ball throw~* Modified Closed Kinetic Chain Upper Extremity Stability Test
Study NCT05150379 — intervention group
Intervention type: BEHAVIORAL
Intervention: SI-RSI questionnaire
Description: French version of Shoulder Instability Return-to-Sport after Injury
Study NCT05044208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG monitoring
Description: After clinical routine diagnostics an additional ambulatory ECG monitoring for 7 days is established
Study NCT04622007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib
Description: Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals
Study NCT04622007 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
Study NCT04622007 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.
Study NCT06222346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CommonGround
Description: Through collaboration with people living with LTCs, clinicians, academics, and web design experts, we have co-designed an online peer support and psychoeducation platform to help people with physical health conditions connect, support others, share experiences, and receive evidence-based information and advice on self-management. The web-based platform offers users access to peer support forums with embedded psychoeducation content.~The following components are key features of the platform:~* A discussion forum~* A private My Garden page that stores posts from other users and psychoeducation content that the user has decided to 'save'.~* A resources page giving access to evidence-based psychoeducation material on the mind-body link~* A 'Crisis and Further Support' page, where users can find further organisations and sources of support, particularly for crisis situations. The peer support platform does not offer one-to-one or crisis support.
Study NCT06222346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS Mental Health
Description: Participants in the control arm will be directed towards the Mental Health webpage(s), an online resources page provided by the NHS. These resources are not specifically targeted at people living with LTCs. They include information sheets and mental health support on topics such as advice for life situations and events. Additionally, it hosts a self-help section that includes guides, tools, and activities to support mental health, but does not include any interactive or peer support elements.
Study NCT06381713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensive combined phonetic-phonological intervention
Description: Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 5 times 30' per week for 2 times 4 weeks.
Study NCT04622007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
Study NCT04622007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Subjects will initiate pemetrexed at 500 mg/m2 intravenously (IV) at a frequency of every 3 weeks.
Study NCT05910866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBAP)
Description: Pacing of the conduction system of the heart to obtain physiological activation
Study NCT05910866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing (RVP)
Description: Conventional ventricular pacing
Study NCT01109888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrotide
Study NCT05224583 — intervention group
Intervention type: PROCEDURE
Intervention: Simultaneous Liver-Kidney Transplant
Description: Simultaneous Liver-Kidney Transplant
Study NCT04756037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix Combination Therapy
Description: Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
Study NCT06381713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensive combined phonetic-phonological intervention
Description: Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 2 times 30' per week for 20 weeks.
Study NCT06016790 — intervention group
Intervention type: GENETIC
Intervention: cfDNA sequencing
Description: Multi-omics sequencing of cfDNA in peripheral venous blood.
Study NCT04993365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT04993365 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT04687696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.